

IMAGE



# Infographic of the European Glaucoma Prevention Study (EGPS)

Ji Eun Han<sup>1</sup> · Rashmi G. Mathew<sup>1</sup> · Christin Henein<sup>1</sup>

Received: 6 December 2020 / Revised: 13 December 2020 / Accepted: 15 January 2021 / Published online: 25 June 2021  
© The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2021, corrected publication 2021




Fig. 1 The European Glaucoma Prevention Study (EGPS) showed that treatment of ocular hypertension with dorzolamide treatment alone did not significantly reduce intraocular pressure or progression to primary open angle glaucoma when compared to treatment with placebo. This result can be explained by the study design, regression to the mean at 6 months in both arms of the study and selective loss to follow-up of participants with higher intraocular pressures. IOP intraocular pressure, POAG primary open angle glaucoma and CI confidence interval.

## Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

✉ Christin Henein  
c.henein@ucl.ac.uk

<sup>1</sup> UCL Institute of Ophthalmology, London, UK